Phase 4
Completed N=15
24-hour IOP-lowering Effect of Brimonidine 0.1%
Source: ClinicalTrials.gov NCT00457795 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Nov 2011
Primary outcomePrimary: Intraocular Pressure (IOP) for a 24-Hour Period at Week 4 — 16.8; 21.1; 23.0 Millimeters of mercury (mmHg)
Summary
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraocular Pressure (IOP) for a 24-Hour Period at Week 4 |
16.8; 21.1; 23.0 | — |
| SECONDARY Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4 |
19.2; 23.1; 22.7; -2.4; -1.9; 0.3 | — |
| SECONDARY Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4 |
46.8; 53.8; 49.2 | — |
| SECONDARY Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4 |
1.1; 0.3; -3.0 | — |
Eligibility Criteria
Inclusion Criteria
- patients with open-angle glaucoma or ocular hypertension
Exclusion Criteria
- allergy to brimonidine
- inability to complete 24 hour stay for monitoring
Data sourced from ClinicalTrials.gov (NCT00457795). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.